TEL AVIV, Sept 14 (Reuters) - Pluristem Therapeutics (PSTI.O) said early clinical trials show its placenta-derived cell therapy is safe and improves quality of life in patients with degenerative disorder peripheral artery disease (PAD).
TEL AVIV, Sept 14 (Reuters) - Pluristem Therapeutics (PSTI.O) said early clinical trials show its placenta-derived cell therapy is safe and improves quality of life in patients with degenerative disorder peripheral artery disease (PAD).
